Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ncardia B V has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, KOSAR, AARON J, who also serves as the busiest examiner for the portfolio. The prosecution is occurring within a distinct art unit, providing a specialized departmental focus for the company's patent applications.
Because KOSAR, AARON J is the only examiner involved, the company can expect a consistent application of examination standards for its pending matter. The practitioner should focus on the specific history and tendencies of the busiest examiner to optimize the prosecution strategy. This concentration within the Biotechnology & Pharmaceuticals field allows for a more efficient and targeted review process.
The evaluation of the pending office action within a distinct art unit suggests that the company's technology is being reviewed by experts in the relevant field. This departmental focus can be an advantage for ensuring that the examination is both thorough and fair. Successfully navigating the requirements of the busiest examiner and the art unit is key to achieving the company's patent goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, AARON J | 1 | 71.3% | +29.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18737048 | CULTURE MEDIUM COMPOSITION FOR MATURATING CARDIOMYOCYTES DERIVED FROM PLURIPOTENT MAMMALIAN STEM CELLS | KOSAR, AARON J | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18737048 | CULTURE MEDIUM COMPOSITION FOR MATURATING CARDIOMYOCYTES DERIVED FROM PLURIPOTENT MAMMALIAN STEM CELLS | KOSAR, AARON J | 1655 | §103§112DP | Non-Final OA | — | Pending | Jun 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNcardia B V has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Aaron J Kosar has the most, with 1 of Ncardia B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
